https://rbfhss.org.br/sbrafh <p>Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde [Brazilian Journal of Hospital Pharmacy and Health Services] is the official scientific journal of the Brazilian Society of Hospital Pharmacy and Health Services - SBRAFH since 2010. RBFHSS does not charge submission or publication fees or article processing charges. RBFHSS is international circulation peer reviewed journal, publishing articles about pharmaceutical services, clinical pharmacy, patient safety, pharmacotherapy, pharmacogenetics, integrative and complementary practices, health technology assessment, hospital pharmacotechnics, applied legislation, waste management, drug stability, and compatibility, pharmacoeconomics, pharmacoepidemiology, and pharmacovigilance.</p> Sociedade Brasileira de Farmácia Hospitalar e Serviços de Saúde en-US Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde 2179-5924 <p>The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.</p> <p>Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" target="_blank" rel="noopener">Creative Commons Attribution License</a> (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.</p> <p>&nbsp;</p> <p><strong>Serlf-archiving policy</strong></p> <p>This journal permits and encourages authors to post and<strong> archive the final pdf</strong> of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.</p> https://rbfhss.org.br/sbrafh/article/view/1184 Elaine Silva MIRANDA Simone Pozza MAHMUD Copyright (c) 2024 Authors https://creativecommons.org/licenses/by-nc-nd/4.0/ 2024-07-15 2024-07-15 15 3 e1184 e1184 10.30968/rbfhss.2024.153.1184 https://rbfhss.org.br/sbrafh/article/view/1153 <p>Objective: this work aims to simulate the economic impact of the introduction of rivaroxaban for venous thromboembolism (VTE) prophylaxis, when compared to the therapeutic options used in the institution (unfractionated heparin and enoxaparin), in the period from January to February 2022. Methods: In a retrospective study, we analyzed the possibility of replacing the prophylaxis used in the institution with prophylaxis with rivaroxaban based on the analysis of data from the electronic medical record system, taking into account the length of stay, the medications prescribed and compliance with the institutional protocol. Patients prescribed medication for VTE prophylaxis and indicated according to progress in the medical record were included, excluding those using non-pharmacological prophylaxis. Patients with contraindications to the use of rivaroxaban, such as pregnancy and liver impairment, were also excluded. Monte Carlo Simulation was used to calculate the cost of treatment with DOACs (Direct Oral Anticoagulants), using the medicines acquisition values during the study period, and a decision tree was constructed. Results: A total of 157 patients who were prescribed one of the heparins were evaluated. Of these patients, 98 (62.4%) could undergo prophylaxis with rivaroxaban as they had no contraindication to this treatment (price recorded in January/February 2022: R$ 0.23). This new prophylaxis would generate savings of up to 98.4% for enoxaparin 40 mg (price recorded in January/February: R$ 14.26), the item that had the highest consumption, corresponding to 71.4% of patients who could use it rivaroxaban. Conclusion: The implementation of rivaroxaban for venous thromboembolism prophylaxis replacing enoxaparin proved to be beneficial in terms of costs for the hospital, which suggests that more studies should be carried out in order to increase the robustness of results and support the incorporation of this technology in the institution.</p> Diovanna Santos DE CARVALHO Rafael Alves DE SOUZA Andrea Cassia SFORSIN Vanusa Barbosa PINTO Maria Cleusa MARTINS Cleber Esteves CHAVES Copyright (c) 2024 Authors https://creativecommons.org/licenses/by-nc-nd/4.0/ 2024-07-11 2024-07-11 15 3 e1153 e1153 10.30968/rbfhss.2024.153.1153